Compounded vs. FDA-Approved GLP-1s: What the FDA Actually Says in 2026

Compounding and FDA approval describe different regulatory pathways. A low advertised price does not establish that a drug is appropriate for you. This guide explains key FDA concerns and questions to discuss with a licensed clinician.

1. Compounded is not generic, and it is not FDA-approved

A generic drug has been reviewed by the FDA and shown to be equivalent to the brand product. A compounded drug does not undergo FDA premarket review for safety, effectiveness or quality. The FDA states directly that compounded drugs are not FDA approved, which means the agency does not evaluate them for safety, effectiveness or quality before they reach patients.

The providers themselves generally say this, in small type. TrimRx's terms state its compounded product is neither FDA-approved nor a generic. WellMedr carries the required notice that compounded GLP-1s have not been evaluated by the FDA. They are not hiding it. They are just not leading with it.

2. The FDA's position on when compounding is appropriate is narrower than the marketing suggests

FDA recommends compounded drugs only when a patient has medical needs that an FDA-approved drug cannot meet. A lower price alone does not establish a clinical need for compounding. Discuss appropriate approved treatments, access barriers and any proposed compounded prescription with a licensed clinician. The FDA also sets conditions on compounding copies of commercially available drugs; a prescription does not remove those conditions.

3. Some ingredients being marketed cannot legally be compounded at all

This is the sharpest line in the FDA's guidance and the one we would most want a reader to remember. Retatrutide and cagrilintide cannot be used in compounding under federal law. They are not components of any FDA-approved drug and have not been found safe and effective for any condition. The FDA says it has warned telehealth companies for marketing unapproved drugs including retatrutide, warned ingredient distributors for selling it to compounders, and warned outsourcing facilities for repackaging it.

If a telehealth brand offers you retatrutide, you are not getting an early look at the next generation of weight-loss medicine. You are buying something outside the legal compounding framework. Walk away.

4. Salt forms of semaglutide are a red flag

The FDA notes that some compounded products use salt forms — semaglutide sodium or semaglutide acetate — which are different active ingredients from the one in the approved drugs. The agency says it is not aware of any lawful basis for using them in compounding. If a provider will not tell you plainly which form of the active ingredient it dispenses, that is information in itself. Practical version: ask which form is dispensed in writing before you pay, and treat a plain, specific answer as a minimum qualification rather than a courtesy.

5. Dosing errors are a documented, repeated harm

The FDA reports receiving multiple adverse event reports, some involving hospitalisation, that may relate to dosing errors with compounded injectable semaglutide — patients measuring and self-administering the wrong amount, and in some cases clinicians miscalculating doses. It also reports adverse events that may relate to patients being prescribed doses beyond what appears on the approved label, whether by larger single doses, more frequent doses, or faster titration.

Containers and concentrations can vary. If your prescription requires measuring medicine from a vial, ask the prescriber or pharmacist to demonstrate the prescribed amount and provide written instructions. Do not calculate a dose from a different product's instructions. See the FDA dosing-error alert.

6. Cold chain: if it arrives warm, do not use it

Injectable GLP-1s require refrigeration. The FDA says it has received complaints that some compounded GLP-1 shipments arrived warm or with inadequate ice packs, and its recommendation is blunt: do not use an injectable GLP-1 that arrives warm or insufficiently refrigerated. This is one reason we treat overnight or expedited shipping as a real feature rather than a marketing garnish when we compare providers.

7. Fraudulent and counterfeit product is circulating

The FDA says it is aware of fraudulent compounded semaglutide and tirzepatide sold in the US carrying false label information — in some cases naming compounding pharmacies that do not exist, in others naming real pharmacies that did not make the product. It is also aware of counterfeit Ozempic in the US market. Separately, the agency has established an import alert covering GLP-1 active pharmaceutical ingredients with potential quality concerns. Practical version: get the name and state of the pharmacy that will fill your prescription in writing, check that name against the state board of pharmacy lookup, and photograph the label the day the box arrives so you have a record if the two do not match.

8. The adverse event numbers, and why they understate things

As of May 31, 2026, the FDA reported having received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The agency also points out that state-licensed pharmacies that are not outsourcing facilities are not required by federal law to report adverse events, so the true count is likely higher. It also notes that many reported events look similar to those seen with the approved versions.

We are not presenting these numbers as proof that compounded GLP-1s are dangerous. Reporting counts are not rates, and there is no denominator here. We are presenting them because they exist, they are official, and nobody selling you a subscription is going to mention them.

9. Approved-drug names on a compounded menu

This is the pattern we now check for first, because we keep finding it. A provider’s homepage advertises the approved medications by name — Wegovy, Zepbound, and newer arrivals — and then the actual catalogue sells compounded product. SkinnyRx is a live example: its homepage promotes "FDA-approved Wegovy, Foundayo and other GLP-1s," but on the product pages both Wegovy Pill and Foundayo are marked Unavailable, with no price attached. The only things you can actually buy are compounded semaglutide and compounded tirzepatide. We wrote that up in our SkinnyRx review.

This is not necessarily deceptive on purpose — supply of the branded products moves, and a site can lag. But the effect on a shopper is the same either way: you arrive believing you are buying an FDA-approved drug and you leave with a compounded one, which is a materially different product with a materially different regulatory status. Everything in the eight points above applies to what you actually receive, not to what was advertised on the way in.

The counter-example is worth naming too. Embody places the FDA compounding disclaimer directly underneath the price on the page where you choose a plan, rather than burying it in a footer. You can disagree with the business model and still recognise that as the right place to put the disclosure. Detail in our Embody review.

What to do: before you pay, open the product page for the specific medication you think you are buying and confirm three things — that it has a price, that it is in stock, and that the page says either "FDA-approved" or "compounded." If the site will not tell you which one you are getting, that is your answer.

10. What the five newest providers say about all this

We added five more providers to our comparison in August 2026, and read their disclosure language the same way.

Oak gave the most candid answer we found. Its FAQ says directly that compounded GLP-1s are not FDA-approved as finished products, while explaining that the ingredients used are FDA-compliant. An ingredient-compliance claim does not mean the finished compounded drug is FDA-approved.

CoreAge Rx puts the word compounded in its product names, which is the right placement. Its terms of use, however, run to roughly thirty thousand words and contain no mention of compounding or of the FDA at all. Oak’s terms of use are longer still and also contain no FDA mention.

Care Bare Rx carries the required disclaimer that compounded medication is not evaluated by the FDA for safety or effectiveness, and then quotes clinical trial results generated with FDA-approved Ozempic on the same page selling compounded product. It also describes oral options as available “through compounded or research-based prescribing”. Research-based prescribing is not a recognised regulatory category.

Synergy Rx and Direct Meds make no mention of the FDA in their terms or on their weight-loss pages. Synergy Rx does put the word compounded in its product names.

Provider-by-provider detail is in the Oak, CoreAge Rx, Care Bare Rx, Synergy Rx and Direct Meds reviews.

The FDA's own telehealth warning signs, in plain language

The agency publishes a list of red flags for buying medication through telehealth companies. Paraphrased, be wary if a company:

• tells you its compounded drug is the same as the FDA-approved drug;
• offers prices that are implausibly low;
• sends medication that looks different from what you have received before, or arrives damaged or without usage instructions;
• does not require screening and a prescription from a licensed clinician;
• has no licensed clinician available to answer questions after the medication arrives;
• has spelling errors on the label or lists an incorrect pharmacy address;
• names a pharmacy on the label that you cannot verify exists.

That last one is checkable in about two minutes. Every state has a searchable pharmacy licence lookup. Do it before your second refill, not after a problem.

What we do with this when we review providers

Our reviews assess what a provider publicly discloses, including ingredient descriptions, pharmacy information, shipping terms and access to a clinician. Those checks do not establish that a medicine is suitable for an individual, or verify the quality of a dispensed product. See our review method.

Source

Related comparisons and guides

• Compounded semaglutide prices compared across every provider
• Compounded tirzepatide prices compared
• Oral and sublingual GLP-1s: who sells them and what is actually approved
• Fourteen red flags to check before you pay
• The full provider comparison

Medical note